Name (Synonyms) | Correlation | |
---|---|---|
drug1925 | Norovirus Bivalent (GI.1 / GII.4) Vaccine(high) Wiki | 1.00 |
drug184 | Aluminum adjuvant Wiki | 1.00 |
drug1927 | Norovirus Bivalent (GI.1 / GII.4) Vaccine(middle) Wiki | 1.00 |
drug1922 | Normal saline Wiki | 0.45 |
drug2707 | Standard of care Wiki | 0.23 |
drug752 | Convalescent Plasma Wiki | 0.20 |
Name (Synonyms) | Correlation | |
---|---|---|
D005759 | Gastroenteritis NIH | 0.71 |
D017250 | Caliciviridae Infections NIH | 0.71 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
A total of 450 subjects were enrolled, divided into four age groups, including 18-59 years, 6-17 years, 3-5 years, and 6-35 months. There are three types of the test vaccine component in each age group. A total of 30 people in each dose group were vaccinated with the test vaccine or placebo 1 or placebo 2, respectively, in a ratio of 3: 1: 1. The 18-59-year-old, 6-17-year-old, and 3-5-year-old age groups were vaccinated 2 times at a time interval of 28 days. The 6-35 month age group is divided into two groups, Group 1 is inoculated with 2 doses interval of 28 days each, and Group 2 is inoculated with 3 doses interval of 28 days.
Description: Active AE: Local and systemic adverse reactions occurring within 0-7 days after each dose of vaccination
Measure: All active AEs within 0-7 days after each dose Time: 7 daysDescription: Adverse events other than active AE include solicitation adverse events reported in addition to the specified solicitation time window
Measure: All non-active collection AEs within 0-28(30) days after each dose Time: 28(30) days